The mRNA Survival Test: Arcturus Therapeutics Bets on Inhaled Cystic Fibrosis Therapy After COVID Revenue Collapse

Arcturus Therapeutics was founded in 2013 and went public in May of the same year, long before messenger RNA technology captured the world's attention. The company spent its early years developing a proprietary mRNA platform built around LUNAR, its lipid nanoparticle delivery system. When the COVID-19 pandemic arrived, Arcturus was positioned to compete in the global vaccine race. It partnered with CSL to develop LUNAR-COVID, a self-amplifying mRNA vaccine candidate that generated hundreds of millions of dollars in collaboration revenue.

That revenue stream has collapsed. In the first quarter of 2026, Arcturus reported total revenue of $0.61 million, a drop of $27.3 million compared to the same period in 2025. The decline was driven almost entirely by reductions in activity under the CSL collaboration. Full-year 2025 revenue decreased by $70.3 million versus 2024. The pandemic-era demand that once filled Arcturus's coffers receded as governments moved on, stockpiles were deemed sufficient, and the world shifted from emergency response to endemic management.

The financial toll is visible across the balance sheet. Cash and cash equivalents stood at $213.4 million as of March 31, 2026, down from $232.8 million at the end of 2025 and from $293.9 million at the end of 2024. Arcturus burned roughly $80 million over the prior 15 months, a pace that would exhaust its reserves within roughly two and a half years if left unchecked. The company's net loss in Q1 2026 was $26.96 million, with a diluted loss per share of $0.95. That is an improvement from the net loss of $29.08 million in Q4 2025, but the trend is clear: Arcturus is spending cash faster than it is bringing it in.

The company's response to this revenue cliff has been two-pronged: cut costs and extend the runway while building a new pipeline that does not depend on pandemic tailwinds. Research and development expenses fell by $13.4 million year-over-year in Q1 2026, driven by lower manufacturing and clinical costs tied to the LUNAR-COVID program. Arcturus is preserving capital, but it is also spending on its next act.

Arcturus does have a near-term commercial asset. In January 2026, the UK Medicines and Healthcare products Regulatory Agency granted approval for KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine. The approval marks the first regulatory clearance for Arcturus's platform technology outside of emergency use settings. KOSTAIVE uses a self-amplifying mRNA design, a technical differentiator from the conventional mRNA vaccines produced by Pfizer-BioNTech and Moderna. Self-amplifying mRNA requires a smaller initial dose because the RNA instructs cells to replicate the antigen-encoding sequence, theoretically producing a stronger and longer-lasting immune response.

The company has partnered with Meiji for commercialization in Japan, giving it a distribution channel in one of the world's largest pharmaceutical markets. The Japanese partnership provides a path to revenue, but the commercial opportunity is limited. Global COVID vaccine demand has fallen sharply, and the market is now dominated by established players with entrenched supply agreements. KOSTAIVE's approval in the UK and partnership in Japan demonstrate that Arcturus's mRNA platform works and can clear regulatory hurdles. They do not, however, represent a financial lifeline on the scale of the CSL collaboration.

Arcturus's most ambitious bet is ARCT-032, an inhaled mRNA therapy for cystic fibrosis. Cystic fibrosis is a genetic disorder caused by mutations in the CFTR gene, leading to thick mucus buildup in the lungs and other organs. Current standard-of-care therapies, such as CFTR modulators from Vertex Pharmaceuticals, have transformed the treatment landscape for patients with specific genetic mutations. But a significant portion of the cystic fibrosis population carries mutations that are not responsive to existing modulators, leaving a clear unmet medical need.

ARCT-032 is designed to deliver mRNA encoding the full-length CFTR protein directly to lung cells via inhalation. The approach is conceptually straightforward: supply the genetic instructions for a functional CFTR protein, and the patient's own cells produce it. The execution, however, faces a fundamental challenge that CEO Joseph Payne articulated directly on the Q1 2026 earnings call.

The company initiated enrollment in a 12-week Phase II study of ARCT-032 in the first half of 2026. The study is designed to evaluate safety and tolerability over a continuous 12-week dosing period, a duration that has no precedent in inhaled mRNA therapy. If ARCT-032 succeeds, it would open a new class of chronic inhaled mRNA treatments. If it fails on safety or tolerability, the setback would cast doubt on the broader inhaled mRNA approach.

The Phase II study's dual focus on safety and early efficacy signals reflects a realistic assessment of the challenge. Inhaled mRNA therapies face unique biological barriers: the lung's immune defenses, the mucociliary escalator that clears particles from the airways, and the potential for inflammation from repeated dosing of foreign mRNA sequences. Arcturus is attempting to demonstrate that its LUNAR delivery platform can overcome these barriers for chronic use, a claim no company has yet proven.

Arcturus has taken deliberate steps to ensure it has enough cash to see its pipeline through key inflection points. The company appointed Dennis Mulroy as Chief Financial Officer in the first quarter of 2026, bringing in a finance executive to oversee a period of tight capital allocation. Mulroy's first order of business was to communicate a clear runway timeline.

The cash runway projection gives Arcturus roughly two years from the date of the Q1 2026 report to either generate significant revenue from its commercial partnerships or produce data that can attract partnership or licensing deals for its pipeline. The $213.4 million on hand is not an unlimited war chest, but it is a survivable buffer for a company of Arcturus's scale.

Cost controls are visible across the operating statement. R&D expenses decreased by $13.4 million year-over-year, a reduction achieved primarily by winding down manufacturing and clinical activities for the LUNAR-COVID program. General and administrative costs have also been managed carefully. The net loss of $26.96 million in Q1 2026 represents a burn rate that, if held steady, would consume cash at a pace consistent with the stated runway beyond mid-2028.

Cystic fibrosis is not the only rare disease target in Arcturus's pipeline. The company is also developing ARCT-810, an mRNA therapy for ornithine transcarbamylase deficiency, a rare urea cycle disorder that affects the liver's ability to remove ammonia from the bloodstream. OTC deficiency is a classic orphan indication: a small patient population with limited treatment options and high unmet medical need. An effective mRNA therapy could provide a life-changing alternative for patients who currently rely on metabolic management, ammonia-scavenging drugs, or liver transplantation.

Arcturus held Type C meetings with the FDA in the first half of 2026 to discuss the pediatric development strategy for ARCT-810. Type C meetings are formal interactions with the agency to align on study design, endpoints, and registration pathways. The fact that Arcturus initiated these discussions signals that management is thinking beyond Phase II data and planning for potential registration trials.

The appointment of Dr. Alan Cohen as Chief Medical Officer in Q1 2026 reinforces the company's focus on clinical execution. Cohen brings experience in rare disease drug development, and his mandate includes overseeing both the CF and OTC deficiency programs. Together, ARCT-032 and ARCT-810 represent Arcturus's strategy of applying its mRNA platform to rare diseases with clear biological targets and defined regulatory pathways. The bet is that a platform initially developed for pandemic response can find its true commercial and medical value in small, underserved patient populations.

Arcturus Therapeutics enters the second half of 2026 with a clear timeline and a narrow set of variables that will determine its future. The company has cash through the second quarter of 2028. It has a regulatory approval in hand for KOSTAIVE and a commercialization partner in Japan. It has two rare disease programs in Phase II development. And it has a CEO who is willing to state the central challenge of the company's strategy in plain terms.

The critical milestones over the next 18 to 24 months include Phase II data readouts for ARCT-032, FDA feedback on the pediatric strategy for ARCT-810, and the commercial uptake of KOSTAIVE in Japan. Any of these outcomes could meaningfully extend Arcturus's financial runway or provide the clinical validation that attracts partnership interest. Failure on any front narrows the options.

The September 2025 lawsuit against AbbVie and Capstone Therapeutics serves as a reminder that Arcturus is not purely a clinical-stage company operating in a vacuum. The lawsuit, filed in the midst of the pipeline transition, reflects a company willing to protect its intellectual property and contractual rights aggressively. It also signals that Arcturus sees its platform as having value worth defending in court, not just in the clinic.

Arcturus has the pieces in place for a turnaround. The self-amplifying mRNA platform is validated by regulatory approval. The cash position, while declining, is sufficient for a deliberate strategy. The rare disease programs address real unmet needs with clear biology. But the central tension remains unresolved: a small company with a thin revenue stream is betting its future on a treatment class that has never been shown to work safely beyond one month of continuous dosing.

The clinical data that will answer that question is still being collected. Until then, Arcturus is a company living on its cash, its platform, and the conviction of its leadership.